Últimas noticias sobre Herc Holdings (NYSE:HRI) Bolsa

Herc Hldgs

Herc Holdings

Herc Holdings Inc is an equipment rental company that was spun out of Hertz Global in 2016. It is currently the equipment rental company (4% market share) in North America, after United Rentals and Sunbelt Rentals, with a fleet size of $6.4 billion. It serves commercial and residential construction customers, the environmental sector, industrial entities, and entertainment production companies. During much of its 50-year-plus history, the company has rented equipment such as aerial lifts to its customers for intermittent use. More recently, it has broadened its catalog to include a host of specialty items. Separately, Herc Holdings' prepares now to incorporate long-term rentals to industrial customers where Herc maintains its own staff at the customer site.

Herc Holdings Inc

Horiba Ltd

WIIM

VSEC

VSE shares are trading higher after the company reported better-than-expected Q1 financial results and issued FY25 sales guidance above estimates.

Raymond James analyst James Rollyson maintains Tidewater (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDW#NYSE">TDW</a>) with a Outperform and lowers the price target from $76 to $70.

News

Price Target

Analyst Ratings

Raymond James Maintains Outperform on Tidewater, Lowers Price Target to $70

POWL

Powell Industries shares are trading lower after the company reported worse-than-expected Q2 sales results.

UBS analyst Dennis Geiger maintains Portillos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTLO#NASDAQ">PTLO</a>) with a Neutral and lowers the price target from $15 to $12.

PTLO

UBS Maintains Neutral on Portillos, Lowers Price Target to $12

Elanco Animal Health Incorporated  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) reported first-quarter 2025 adjusted earnings per share of 37 cents. That&#8217;s up <a href="https://www.benzinga.com/insights/short-sellers/25/05/45254303/is-the-market-bullish-or-bearish-on-elanco-animal-health">9% year over year</a>.
The company beat the management guidance of 29 to 34 cents and <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">the consensus of 31 cents</a>.
Elanco reported sales of $1.19 billion. It beat the consensus of $1.17 billion and the management <a href="https://www.benzinga.com/general/health-care/25/02/43951589/elanco-animals-outlook-lags-street-expectations-but-analyst-sees-time-for-elancos-commercial-investment-to-payoff" target="_blank" rel="noreferrer noopener">guidance of $1.16 billion-$1.18 billion</a>.
Sales decreased 1% on a reported basis and increased 4% on organic constant currency growth.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45208077/elanco-animal-health-sells-xdemvy-royalties-to-blackstone-in-295-million-deal-to-lower-debt" rel="noreferrer noopener">Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal</a>
Pet Health revenue was $635 million. That&#8217;s a decrease of 1% on a reported basis. However, it&#8217;s an increase of 1% when excluding foreign exchange rates, including a 2% increase from price, compared to <a href="https://www.benzinga.com/pressreleases/25/05/n45247375/elanco-animal-health-reports-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">the first quarter of 2024</a>.
<ul>
<li>The year-over-year volume decline in the first quarter was primarily driven by a challenging U.S. retail environment in the first quarter of 2025, and decreased vaccine sales in the U.S., mainly offset by increased sales of new products and continued strong demand for parasiticide products in Europe.</li>
<li>The Advantage&nbsp;Family of products and Seresto&nbsp;contributed revenue of&nbsp;$123 million&nbsp;and&nbsp;$153 million, respectively.&nbsp;</li>
</ul>
Farm Animal revenue was&nbsp;$546 million, a decrease of 2% on a reported basis, or an increase of 7% when excluding the unfavorable impacts from the aqua divestiture and foreign exchange rates, driven by a 3% increase from price.
<ul>
<li>First quarter volumes were up 4%, primarily driven by strength in U.S. cattle, led by Experior.</li>
</ul>
Adjusted EBITDA was&nbsp;$276 million, a decrease of 6%. Adjusted EBITDA margin was 23.1% compared to 24.4% a year ago.
As of March 31, Elanco&#8217;s net leverage ratio was 4.4x adjusted EBITDA, an increase of 0.1x compared to December 31, 2024, and expects gross debt paydown of $450 million-$500 million in 2025.
Guidance: &#8220;We are raising our 2025 full-year revenue guidance and maintaining our adjusted EBITDA and adjusted EPS ranges, reflecting our strong first quarter execution, recent momentum and more favorable foreign exchange rates, balanced by expected tariff impact and a cautious approach in an uncertain macroeconomic environment,&#8221; said .
Tariffs: Elanco is taking &#8220;several intervention actions&#8221; that will position the company to cover potential impacts with or without the pharmaceutical exemption, CFO Todd Young said.
While we are taking a prudent approach to the balance of the year given the dynamic macroeconomic backdrop, our durable portfolio and solid momentum bolster our confidence in sequential acceleration of revenue growth to deliver our 2025 goals while creating long-term value for shareholders and society,&#8221; said&nbsp;Jeff Simmons, President and CEO.
Elanco Animal Health raises fiscal 2025 revenue guidance from $4.45 billion-$4.51 billion to $4.51 billion-$4.58 billion versus the consensus of $4.484 billion.
Elanco Animal reaffirms its 2025 adjusted EPS of 80-86 cents versus the consensus of 83 cents.
What&#8217;s Next: Elanco expects second-quarter 2025 adjusted earnings of 17-21 cents compared to the consensus of 25 cents, with sales of $1.175 billion-$1.195 billion compared to the consensus of $1.17 billion.
Price Action:&nbsp;ELAN stock is up 17.4% at $11.17 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/05/45237813/tactile-systems-stock-tumbles-as-q1-earnings-fall-short-of-expectations" target="_blank" rel="noreferrer noopener">Tactile Systems Stock Tumbles As Q1 Earnings Fall Short Of Expectations</a></li>
</ul>

Earnings

Large Cap

Guidance

Health Care

Movers

Trading Ideas

General

ELAN

Animal Health Elanco Chirps A Solid Quarter Tempered By Soft Q2 EPS Guide

WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-08. Here's a quick overview of what investors should know before the release.
Analysts are estimating that WAVE Life Sciences will report an earnings per share (EPS) of $-0.25.
The market awaits WAVE Life Sciences's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.39, leading to a 5.88% drop in the share price on the subsequent day.
Here's a look at WAVE Life Sciences's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.22</td>
<td>-0.28</td>
<td>-0.21</td>
<td>-0.21</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.17</td>
<td>-0.47</td>
<td>-0.25</td>
<td>-0.24</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-6.0%</td>
<td>-1.0%</td>
<td>-6.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746630201_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of WAVE Life Sciences were trading at $6.41 as of May 06. Over the last 52-week period, shares are up 14.67%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analysts' Perspectives on WAVE Life Sciences</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding WAVE Life Sciences.
Analysts have provided WAVE Life Sciences with 4 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $20.0, suggesting a potential 212.01% upside.
<h3>Comparing Ratings with Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of Ocular Therapeutix, Pacira BioSciences and Harrow, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Ocular Therapeutix, with an average 1-year price target of $15.83, suggesting a potential 146.96% upside.</li>
<li>Analysts currently favor an Buy trajectory for Pacira BioSciences, with an average 1-year price target of $44.6, suggesting a potential 595.79% upside.</li>
<li>Analysts currently favor an Buy trajectory for Harrow, with an average 1-year price target of $59.0, suggesting a potential 820.44% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
The peer analysis summary offers a detailed examination of key metrics for Ocular Therapeutix, Pacira BioSciences and Harrow, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amphastar Pharma</td>
<td>Neutral</td>
<td>4.73%</td>
<td>$86.65M</td>
<td>5.20%</td>
</tr>
<tr>
<td>Ocular Therapeutix</td>
<td>Buy</td>
<td>15.41%</td>
<td>$15.85M</td>
<td>-14.50%</td>
</tr>
<tr>
<td>Pacira BioSciences</td>
<td>Buy</td>
<td>3.32%</td>
<td>$147.37M</td>
<td>2.10%</td>
</tr>
<tr>
<td>Harrow</td>
<td>Buy</td>
<td>83.83%</td>
<td>$52.70M</td>
<td>10.62%</td>
</tr>
</tbody>
</table>

Key Takeaway:
WAVE Life Sciences ranks in the middle among its peers for Consensus rating. It is at the bottom for Revenue Growth and Gross Profit, but at the top for Return on Equity.
<h3>Get to Know WAVE Life Sciences Better</h3>
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
<h3>A Deep Dive into WAVE Life Sciences's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining WAVE Life Sciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 188.23% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: WAVE Life Sciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 34.93%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): WAVE Life Sciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 16.66%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): WAVE Life Sciences's ROA stands out, surpassing industry averages. With an impressive ROA of 8.23%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.12, WAVE Life Sciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/WVE/earnings">To track all earnings releases for WAVE Life Sciences visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WAVE Life Sciences Earnings Preview

Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-08. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Akebia Therapeutics will report an earnings per share (EPS) of $-0.04.
The announcement from Akebia Therapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.02, leading to a 33.73% increase in the share price on the subsequent day.
Here's a look at Akebia Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.08</td>
<td>-0.06</td>
<td>-0.05</td>
<td>-0.08</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.10</td>
<td>-0.10</td>
<td>-0.04</td>
<td>-0.09</td>
</tr>
<tr>
<td>Price Change %</td>
<td>34.0%</td>
<td>4.0%</td>
<td>-7.000000000000001%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746630193_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Akebia Therapeutics were trading at $2.32 as of May 06. Over the last 52-week period, shares are up 80.08%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/AKBA/earnings">To track all earnings releases for Akebia Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKBA

Insights Ahead: Akebia Therapeutics's Quarterly Earnings

RXO shares are trading lower after the company reported worse-than-expected Q1 financial results.

Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-08. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Novavax will report an earnings per share (EPS) of $0.19.
The market awaits Novavax's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.00, leading to a 17.99% increase in the share price on the subsequent day.
Here's a look at Novavax's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.51</td>
<td>-0.83</td>
<td>1.36</td>
<td>-1.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.51</td>
<td>-0.76</td>
<td>0.99</td>
<td>-1.05</td>
</tr>
<tr>
<td>Price Change %</td>
<td>18.0%</td>
<td>-8.0%</td>
<td>-1.0%</td>
<td>99.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746630170_0.png" alt="eps graph" />
<h3>Market Performance of Novavax's Stock</h3>
Shares of Novavax were trading at $6.07 as of May 06. Over the last 52-week period, shares are up 35.01%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/NVAX/earnings">To track all earnings releases for Novavax visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NVAX

Uncovering Potential: Novavax's Earnings Preview

JAZZ

Jazz Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 financial results and cut its FY25 adjusted EPS guidance. Also, Piper Sandler and Morgan Stanley lowered their respective price targets on the stock.

Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-08. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Intellia Therapeutics to report an earnings per share (EPS) of $-1.27.
Anticipation surrounds Intellia Therapeutics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.05, leading to a 7.09% drop in the share price on the subsequent day.
Here's a look at Intellia Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.32</td>
<td>-1.38</td>
<td>-1.23</td>
<td>-1.38</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.27</td>
<td>-1.34</td>
<td>-1.52</td>
<td>-1.12</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-7.000000000000001%</td>
<td>5.0%</td>
<td>-4.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746630145_0.png" alt="eps graph" />
<h3>Performance of Intellia Therapeutics Shares</h3>
Shares of Intellia Therapeutics were trading at $7.25 as of May 06. Over the last 52-week period, shares are down 70.49%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/NTLA/earnings">To track all earnings releases for Intellia Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NTLA

A Glimpse of Intellia Therapeutics's Earnings Potential

Disclosed in the latest SEC filing, a significant insider purchase on May 6, involves Darrell L Ford, Board Member at Illinois Tool Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>).
What Happened: In a recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000049826/000004982625000021//Archives/edgar/data/49826/000004982625000021/0000049826-25-000021-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday, Ford increased their investment in Illinois Tool Works by purchasing 907 shares through open-market transactions, signaling confidence in the company's potential. The total transaction value is $219,784.
Tracking the Wednesday's morning session, Illinois Tool Works shares are trading at $237.17, showing a down of 1.13%.
<h3>Unveiling the Story Behind Illinois Tool Works</h3>
Founded in 1912, Illinois Tool Works has become a diversified industrial manufacturer through acquisitions and innovations that follow customer needs. ITW operates through seven business segments, with no segment representing more than one fifth of revenue. ITW's automotive OEM segment sells vehicle components; its food equipment segment sells commercial kitchen appliances; its test &amp; measurement and electronics segment sells inspection and analysis equipment; its welding segment sells welding equipment and consumables; its polymers &amp; fluids segment sells industrial and consumer adhesives, solvents, and coatings; its construction products segment sells building fasteners and tools; and its specialty products segment sells medical, packaging, HVAC, and airport ground equipment.
<h3>Illinois Tool Works: Delving into Financials</h3>
Revenue Growth: Illinois Tool Works's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -3.37%. This indicates a decrease in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 43.71%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Illinois Tool Works's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 2.39.
</li>
</ul>
Debt Management: Illinois Tool Works's debt-to-equity ratio surpasses industry norms, standing at 2.55. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: Illinois Tool Works's P/E ratio of 21.12 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 4.51 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 15.79 reflects market recognition of Illinois Tool Works's value, positioning it as more highly valued compared to industry peers.
</li>
</ul>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000049826">Check Out The Full List Of Illinois Tool Works's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Bullish Move: Darrell L Ford Shows Confidence, Acquires $219K In Illinois Tool Works Stock

UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Neutral and lowers the price target from $16 to $7.

MYGN

UBS Maintains Neutral on Myriad Genetics, Lowers Price Target to $7

Xeris Biopharma Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XERS#NASDAQ">XERS</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-08. Here's what investors need to know before the announcement.
Analysts estimate that Xeris Biopharma Holdings will report an earnings per share (EPS) of $-0.04. 
Investors in Xeris Biopharma Holdings are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company missed EPS by $0.01, leading to a 2.66% increase in the share price the following trading session.
Here's a look at Xeris Biopharma Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.02</td>
<td>-0.09</td>
<td>-0.11</td>
<td>-0.12</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.03</td>
<td>-0.11</td>
<td>-0.10</td>
<td>-0.14</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>3.0%</td>
<td>4.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746630131_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Xeris Biopharma Holdings were trading at $4.3 as of May 06. Over the last 52-week period, shares are up 140.46%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/XERS/earnings">To track all earnings releases for Xeris Biopharma Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

XERS

Earnings Outlook For Xeris Biopharma Holdings

A new SEC filing reveals that James W Griffith, Board Member at Illinois Tool Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>), made a notable insider purchase on May 6,.
What Happened: Griffith demonstrated confidence in Illinois Tool Works by purchasing 763 shares, as reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000049826/000117777325000002//Archives/edgar/data/49826/000117777325000002/0001177773-25-000002-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The total value of the transaction is $184,890.
At Wednesday morning, Illinois Tool Works shares are down by 1.13%, trading at $237.17.
<h3>Get to Know Illinois Tool Works Better</h3>
Founded in 1912, Illinois Tool Works has become a diversified industrial manufacturer through acquisitions and innovations that follow customer needs. ITW operates through seven business segments, with no segment representing more than one fifth of revenue. ITW's automotive OEM segment sells vehicle components; its food equipment segment sells commercial kitchen appliances; its test &amp; measurement and electronics segment sells inspection and analysis equipment; its welding segment sells welding equipment and consumables; its polymers &amp; fluids segment sells industrial and consumer adhesives, solvents, and coatings; its construction products segment sells building fasteners and tools; and its specialty products segment sells medical, packaging, HVAC, and airport ground equipment.
<h3>Financial Milestones: Illinois Tool Works's Journey</h3>
Negative Revenue Trend: Examining Illinois Tool Works's financials over 3 months reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -3.37% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 43.71%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 2.39, Illinois Tool Works showcases strong earnings per share.
</li>
</ul>
Debt Management: Illinois Tool Works's debt-to-equity ratio surpasses industry norms, standing at 2.55. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Illinois Tool Works's P/E ratio of 21.12 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 4.51, Illinois Tool Works's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Illinois Tool Works's EV/EBITDA ratio of 15.79 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Breaking Down the Significance of Transaction Codes</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000049826">Check Out The Full List Of Illinois Tool Works's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Move: James W Griffith Invests $184K In Illinois Tool Works Stock

On May 6, Kelly J Grier, Board Member at Illinois Tool Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) executed a significant insider buy, as disclosed in the latest SEC filing.
What Happened: Grier demonstrated confidence in Illinois Tool Works by purchasing 763 shares, as reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000049826/000194586925000003//Archives/edgar/data/49826/000194586925000003/0001945869-25-000003-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The total value of the transaction is $184,890.
At Wednesday morning, Illinois Tool Works shares are down by 1.13%, trading at $237.17.
<h3>Discovering Illinois Tool Works: A Closer Look</h3>
Founded in 1912, Illinois Tool Works has become a diversified industrial manufacturer through acquisitions and innovations that follow customer needs. ITW operates through seven business segments, with no segment representing more than one fifth of revenue. ITW's automotive OEM segment sells vehicle components; its food equipment segment sells commercial kitchen appliances; its test &amp; measurement and electronics segment sells inspection and analysis equipment; its welding segment sells welding equipment and consumables; its polymers &amp; fluids segment sells industrial and consumer adhesives, solvents, and coatings; its construction products segment sells building fasteners and tools; and its specialty products segment sells medical, packaging, HVAC, and airport ground equipment.
<h3>Breaking Down Illinois Tool Works's Financial Performance</h3>
Negative Revenue Trend: Examining Illinois Tool Works's financials over 3 months reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -3.37% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 43.71%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Illinois Tool Works's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 2.39.
</li>
</ul>
Debt Management: Illinois Tool Works's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.55, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Understanding Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 21.12, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 4.51 is above industry norms, reflecting an elevated valuation for Illinois Tool Works's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Illinois Tool Works's EV/EBITDA ratio of 15.79 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Important Transaction Codes</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000049826">Check Out The Full List Of Illinois Tool Works's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Board Member Of Illinois Tool Works Makes $184K Buy

A new SEC filing reveals that E. Scott Santi, Board Member at Illinois Tool Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>), made a notable insider purchase on May 6,.
What Happened: In a recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000049826/000130758125000008//Archives/edgar/data/49826/000130758125000008/0001307581-25-000008-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday, Santi increased their investment in Illinois Tool Works by purchasing 1,938 shares through open-market transactions, signaling confidence in the company's potential. The total transaction value is $469,616.
The latest update on Wednesday morning shows Illinois Tool Works shares down by 1.13%, trading at $237.17.
<h3>Discovering Illinois Tool Works: A Closer Look</h3>
Founded in 1912, Illinois Tool Works has become a diversified industrial manufacturer through acquisitions and innovations that follow customer needs. ITW operates through seven business segments, with no segment representing more than one fifth of revenue. ITW's automotive OEM segment sells vehicle components; its food equipment segment sells commercial kitchen appliances; its test &amp; measurement and electronics segment sells inspection and analysis equipment; its welding segment sells welding equipment and consumables; its polymers &amp; fluids segment sells industrial and consumer adhesives, solvents, and coatings; its construction products segment sells building fasteners and tools; and its specialty products segment sells medical, packaging, HVAC, and airport ground equipment.
<h3>Financial Milestones: Illinois Tool Works's Journey</h3>
Revenue Growth: Illinois Tool Works's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -3.37%. This indicates a decrease in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 43.71%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 2.39, Illinois Tool Works showcases strong earnings per share.
</li>
</ul>
Debt Management: Illinois Tool Works's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.55, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Insights into Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: Illinois Tool Works's P/E ratio of 21.12 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 4.51, Illinois Tool Works's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an impressive EV/EBITDA ratio of 15.79, Illinois Tool Works demonstrates exemplary market valuation, surpassing industry averages.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Breaking Down the Significance of Transaction Codes</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000049826">Check Out The Full List Of Illinois Tool Works's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

E. Scott Santi Boosts Confidence With $469K Purchase Of Illinois Tool Works Stock

XPLR Infrastructure (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XIFR#NYSE">XIFR</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-08. Here's what investors need to know before the announcement.
Analysts estimate that XPLR Infrastructure will report an earnings per share (EPS) of $0.20. 
The announcement from XPLR Infrastructure is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS beat by $0.14, leading to a 11.33% drop in the share price on the subsequent day.
Here's a look at XPLR Infrastructure's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.85</td>
<td>0.61</td>
<td>0.65</td>
<td>0.30</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.99</td>
<td>-0.43</td>
<td>0.66</td>
<td>0.75</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-11.0%</td>
<td>-0.0%</td>
<td>-6.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746630115_0.png" alt="eps graph" />
<h3>Tracking XPLR Infrastructure's Stock Performance</h3>
Shares of XPLR Infrastructure were trading at $8.16 as of May 06. Over the last 52-week period, shares are down 74.63%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analyst Insights on XPLR Infrastructure</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding XPLR Infrastructure.
The consensus rating for XPLR Infrastructure is Underperform, based on 2 analyst ratings. With an average one-year price target of $6.0, there's a potential 26.47% downside.
<h3>Understanding Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Montauk Renewables, Sunnova Energy Intl and ReNew Energy Glb, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Montauk Renewables, with an average 1-year price target of $3.33, suggesting a potential 59.19% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Sunnova Energy Intl, with an average 1-year price target of $0.93, suggesting a potential 88.6% downside.</li>
<li>Analysts currently favor an Buy trajectory for ReNew Energy Glb, with an average 1-year price target of $7.5, suggesting a potential 8.09% downside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
The peer analysis summary presents essential metrics for Montauk Renewables, Sunnova Energy Intl and ReNew Energy Glb, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>XPLR Infr</td>
<td>Underperform</td>
<td>27.27%</td>
<td>$179M</td>
<td>-3.44%</td>
</tr>
<tr>
<td>Montauk Renewables</td>
<td>Neutral</td>
<td>-40.83%</td>
<td>$4.83M</td>
<td>-3.17%</td>
</tr>
<tr>
<td>Sunnova Energy Intl</td>
<td>Neutral</td>
<td>15.42%</td>
<td>$99.34M</td>
<td>-7.88%</td>
</tr>
<tr>
<td>ReNew Energy Glb</td>
<td>Buy</td>
<td>15.50%</td>
<td>$15.90B</td>
<td>-3.52%</td>
</tr>
</tbody>
</table>

Key Takeaway:
XPLR Infrastructure ranks at the bottom for Revenue Growth and Gross Profit among its peers. It is also at the bottom for Return on Equity.
<h3>Discovering XPLR Infrastructure: A Closer Look</h3>
XPLR Infrastructure LP is formed to acquire, manage, and own contracted clean energy projects. It owns interests in wind and solar projects in North America, as well as natural gas infrastructure assets in Texas. Renewable energy assets consist of wind, solar, and solar-plus-storage projects and a stand-alone battery storage project, as well as contracted natural gas pipeline assets. Renewable energy sales generate maximum revenue for the company.
<h3>Financial Insights: XPLR Infrastructure</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: XPLR Infrastructure's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 27.27%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Utilities sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: XPLR Infrastructure's net margin excels beyond industry benchmarks, reaching -38.78%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): XPLR Infrastructure's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -3.44%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): XPLR Infrastructure's ROA stands out, surpassing industry averages. With an impressive ROA of -0.55%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: XPLR Infrastructure's debt-to-equity ratio is below the industry average. With a ratio of 1.65, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/XIFR/earnings">To track all earnings releases for XPLR Infrastructure visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

XIFR

Earnings Outlook For XPLR Infrastructure

Making a noteworthy insider sell on May 6, JAYNIE STUDENMUND, Board Member at ExlService Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXLS#NASDAQ">EXLS</a>), is reported in the latest SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001297989/000162828025022776//Archives/edgar/data/1297989/000162828025022776/0001628280-25-022776-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that STUDENMUND sold 14,580 shares of ExlService Hldgs. The total transaction amounted to $692,987. 
Monitoring the market, ExlService Hldgs's shares down by 0.0% at $46.67 during Wednesday's morning.
<h3>Delving into ExlService Hldgs's Background</h3>
ExlService Holdings Inc. is a business process management company that provides digital operations and analytical services to clients driving enterprise-scale business transformation initiatives that leverage the company's deep expertise in analytics, AI, ML, and cloud. The company offers business process outsourcing and automation services, and data-driven insights to customers across multiple industries. The company operates through four segments based on the products and services offered and markets served: Insurance, Healthcare, Emerging Business, and Analytics . The vast majority of the company's revenue is earned in the United States, and more than half of its revenue comes from Analytics segment.
<h3>Breaking Down ExlService Hldgs's Financial Performance</h3>
Revenue Growth: ExlService Hldgs's remarkable performance in 3 months is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 14.78%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 38.58%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): ExlService Hldgs's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.41.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.38, ExlService Hldgs adopts a prudent financial strategy, indicating a balanced approach to debt management.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 35.36, ExlService Hldgs's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 4.02 is above industry norms, reflecting an elevated valuation for ExlService Hldgs's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): ExlService Hldgs's EV/EBITDA ratio stands at 20.21, surpassing industry benchmarks. This places the company in a position with a higher-than-average market valuation.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Exploring Key Transaction Codes</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001297989">Check Out The Full List Of ExlService Hldgs's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXLS

JAYNIE STUDENMUND Implements A Sell Strategy: Offloads $692K In ExlService Hldgs Stock

Disclosed on May 6, Jamie Iannone, President and CEO at eBay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>), executed a substantial insider sell as per the latest SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001065088/000112760225013505//Archives/edgar/data/1065088/000112760225013505/0001127602-25-013505-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday outlined that Iannone executed a sale of 20,000 shares of eBay with a total value of $1,377,900.
Monitoring the market, eBay's shares down by 0.23% at $70.2 during Wednesday's morning.
<h3>Discovering eBay: A Closer Look</h3>
EBay operates one of the largest e-commerce marketplaces in the world, with $75 billion in 2024 gross merchandise volume rendering the firm a top 10 global e-commerce company. It generates revenue from listing fees, advertising, revenue-sharing arrangements with service providers, and managed payments, with its platform connecting more than 130 million buyers and roughly 20 million sellers across almost 190 global markets at the end of 2024. EBay generates just north of 50% of its GMV in international markets, with a large presence in the UK, Germany, and Australia.
<h3>Key Indicators: eBay's Financial Health</h3>
Revenue Growth: Over the 3 months period, eBay showcased positive performance, achieving a revenue growth rate of 1.13% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 72.03%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): eBay's EPS is below the industry average. The company faced challenges with a current EPS of 1.08. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: eBay's debt-to-equity ratio surpasses industry norms, standing at 1.45. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 16.91, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 3.34 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 11.77 is below the industry average, indicating that it may be relatively undervalued compared to peers.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>The Insider's Guide to Important Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001065088">Check Out The Full List Of eBay's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Herc Holdings

Noticias

Últimas noticias sobre Herc Holdings (NYSE:HRI) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL